Certificate of Analysis

April 17, 2026

PHARMABINOID B.V.
Loopkantstraat 13A
5405 NB Uden

Order No. 583240
Sample No. 1369413

SAMPLE INFORMATION

Description	CBG Isolate
Lot Number	R251215MS53MS127
Category (Type)	Non-Inhalable Concentrate (Isolate)
Received	December 17, 2025

ANALYTICAL RESULTS

Analysis	Cannabinoid Profile (Non-Plant)
Instrument	Liquid Chromatography Diode Array Detector (LC-DAD)
Method	MF-CHEM-15
Analysis Date	December 17, 2025 to December 17, 2025

Cannabinoid	mg/g	%
Δ8-THC	ND	ND
Δ9-THC	ND	ND
Δ9-THCA	ND	ND
THCV	ND	ND
THCVA	ND	ND
CBD	ND	ND
CBDA	ND	ND
CBC	ND	ND
CBCA	ND	ND
CBDV	ND	ND
CBG	998.85	99.885
CBGA	ND	ND
CBN	ND	ND
Total THC	ND	ND
Total CBD	ND	ND
Total Cannabinoids	998.85	99.885
Sum of Cannabinoids	998.85	99.885

Reported by
Anresco, Inc.

Zachary Eisenberg
President

April 17, 2026

NT = Not Tested
ND = None Detected
LOD = Limit of Detection (0.3333 mg/g)
LOQ = Limit of Quantitation (1.0000 mg/g)
Total THC = Δ8-THC + Δ9-THC + (0.877 * THCA)
Total CBD = CBD + (0.877 * CBDA)
Total Cannabinoids = Σ (neutral cannabinoids) + [0.877 * Σ (acidic cannabinoids)]

If there are any questions with this report, please contact "compliance@anresco.com".

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. Sampling was not performed by the laboratory. Results apply only to the sample(s) as received. Anresco Laboratories is ISO/IEC 17025:2017 Accredited by ANAB - Certificate Number AT-1551.